Navigation Links
Kosan Presents Phase 1 Data Showing Promising Antitumor Activity,and Safety Profile of Epothilone KOS-1584 at ASCO

HAYWARD, Calif., June 04, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated presented data from a Phase 1 clinical trial showing that KOS-1584/R1645, an epothilone under co-development with Roche, demonstrated promising antitumor activity and tolerability in patients with solid tumors. KOS-1584/R1645 showed activity in 32% of patients (13 of 41 evaluable) including activity in patients with non-small cell lung, ovarian, breast, prostate, head and neck and other cancers. Common toxicities were generally low-grade and manageable. Data from this ongoing trial were presented on Sunday, June 3, 2007, in a poster titled, "Phase 1 Trial of KOS-1584 (a Novel Epothilone) Using Two Weekly Dosing Schedules," by Howard Burris, M.D., Sarah Cannon Research Institute, Nashville, TN, at the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO).

"Epothilones are promising anticancer agents due to their taxane-like mechanism of action and demonstrated activity in taxane resistant tumors," said Dr. Burris. "Kosan's novel epothilone is of particular interest due to its level of antitumor activity in patients with highly refractory disease and manageable side effect profile. This promising compound warrants continued development."

"KOS-1584/R1645 is a highly potent compound with attractive pharmaceutical properties, including a long half-life, large volume of distribution, wide therapeutic index and ease of formulation that has demonstrated encouraging activity in Phase 1 trials," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "We believe that KOS-1584/R1645, based on our novel epothilone D backbone, has the potential to be superior to other epothilones currently in development and ultimately emerge as a meaningful competitor in the taxane market. We look forward to initiating a robust Phase 2 clinical program, with the support of our partner Roch
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
3. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
4. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
5. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
(Date:12/24/2014)... 2014 Kinex Pharmaceuticals announced today that the ... Park Cancer Institute. KX2-361 (KX02), a dual ... shown potent inhibitory activity against a broad panel of ... to Temozolomide (T98G), the most widely used chemotherapy for ... tumor mouse model, KX2-361 consistently clears brain tumors after ...
(Date:12/24/2014)... CRANBURY, N.J. and FARMINGTON, ... Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical ... treatment of diseases with significant unmet medical need ... closed on a private placement of 2,050,000 shares ... to purchase 24,949,325 shares of its common stock.  ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 25, 2014 Recently, BellasDress ... all its wedding dresses. BellasDress has chosen their best-selling ... gift choices for the holiday season. , Now, ... suitable wedding gowns here at discount prices. The business ... at its website. , “All our elegant ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... News) -- Among early stage breast cancer patients who ... one percent will eventually develop leukemia as a result ... finding comes from a review of more than 20,000 ... it suggests that the risk for developing treatment-related leukemia, ... thought. "The frequency of bone marrow cancers such ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 “ SmileStix ” ... which features the latest and coolest mobile applications on the ... expert and host of NewsWatch, conducted the app review and ... to create personal stickers. , The old saying goes, “A ... lot of words that can describe a single image, because ...
Breaking Medicine News(10 mins):Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3Health News:An Application to Create Custom Stickers was Featured on NewsWatch Television on December 19, 2014 2
... , Projects Target Medical Center Upgrades, Energy Efficiency ... of Veterans Affairs Eric K. Shinseki announced today the Department of Veterans ... share of spending under the American Recovery and Reinvestment Act (ARRA), more ... "In putting America back to work, we are targeting the programs of ...
... 21, 2009 Two subset analyses from the landmark ... bleeding and cardiac death versus the combination of heparin ... myocardial infarction (STEMI) who have disease of the left ... highest risk for death, bivalirudin also confers the greatest ...
... , , SEATTLE, Sept. 21 ... ranked it as the best insurance plan in the state, and ... The survey, which was conducted by the Medical Group ... in which health plans paid claims as well as medical practices, ...
... PASSAIC, N.J., Sept. 21 Back to School season is here ... the chemical insecticide solutions are all true, and the answer lies in ... the counter or by prescription, are designed to kill lice but do ... eggs can hatch and there,s a brand new case of head lice. ...
... FRANKFURT, September 21 Trying ... quality standards and competitve,pressures are making the computer-driven proofreading ... Schlafender Hase GmbH of Frankfurt ... annually RAPS event (Regulatory,Affairs Professionals Society) in Philadelphia showed ...
... ... details about the research, preparation, actual surgery and current results of this ground-breaking procedure. ... (Vocus) September ... surgeons involved are offering full details about the research, preparation, actual surgery and current ...
Cached Medicine News:Health News:Secretary Shinseki Announces Progress on $1.4 Billion in Recovery Act Spending 2Health News:One-year results from Horizons-AMI trial reported at TCT 2009 2Health News:One-year results from Horizons-AMI trial reported at TCT 2009 3Health News:One-year results from Horizons-AMI trial reported at TCT 2009 4Health News:Regence BlueShield Receives Top Marks in Insurance Survey 2Health News:Head Lice Meet Their Natural Match - Leading Experts Say Safe Solution Proves Best for Lice and Nit Removal 2Health News:Value of Text Verification Tool (TVT) Strongly Confirmed at RAPS in Philadelphia 2Health News:Details Emerge About Approach, Results of First US Face Transplant 2
... Instrument program offers state-of-the-art quality in an ... strength and durability. Low profile cutting tips ... spaces. Series I instruments are available in ... and angle required for large and small ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
... The WideBiter Punch series facilitates fast and ... a smooth, anatomically shaped meniscal rim. The ... profile to access even the tightest joint ... California, Inc., 20 years of engineering experience ...
... fast and effective resection of meniscal tears ... rim. The flat, crescent-shaped tip has an ... tightest joint spaces. Made in the U.S. ... engineering experience in arthroscopy hand instrument design ...
Medicine Products: